Form 8-K - Current report:
SEC Accession No. 0001213900-24-096807
Filing Date
2024-11-12
Accepted
2024-11-12 16:15:24
Documents
15
Period of Report
2024-11-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220633-8k425_denali.htm   iXBRL 8-K 31686
2 PRESS RELEASE, DATED NOVEMBER 11, 2024 ea022063301ex99-1_denali.htm EX-99.1 3810
  Complete submission text file 0001213900-24-096807.txt   266740

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE deca-20241111.xsd EX-101.SCH 4218
4 XBRL DEFINITION FILE deca-20241111_def.xml EX-101.DEF 27328
5 XBRL LABEL FILE deca-20241111_lab.xml EX-101.LAB 37879
6 XBRL PRESENTATION FILE deca-20241111_pre.xml EX-101.PRE 25948
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0220633-8k425_denali_htm.xml XML 7481
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 241448377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)